Chinese Medicine Anti-Cancer Evaluation Program, Greg Brown Laboratory, Central Clinical School and Charles Perkins Centre, The University of Sydney, Sydney, Australia; Department of Endocrinology, Royal Prince Alfred Hospital, Sydney, Australia.
Institute of Interdisciplinary Integrative Medicine Research, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
J Ethnopharmacol. 2020 Apr 6;251:112526. doi: 10.1016/j.jep.2019.112526. Epub 2019 Dec 29.
Hedyotis diffusa Willd. (H) and Scutellaria barbata D.Don (S) are ancient anti-cancer Chinese herb medicines. When combined, known as HS, it is one of the most commonly prescribed Chinese Medicines for cancer patients today in China.
The prevention of disease progression is a dominant concern for the growing number of men with prostate cancer. The purpose of this work is to evaluate the action and mode of action of Chinese Medicine recipe HS in inhibiting prostate cancer progression in preclinical models.
Effects of HS were analyzed in prostate cancer cell lines by evaluating proliferation, cell cycle profile, DNA damage and key regulators responsible for G to M phase transition. The transcriptional activities of these regulators were determined by RT-PCR and ChIP. The efficacy of HS in vitro was validated in an animal model.
HS treatment was observed to reduce DNA content and accumulated prostate cancer cells at the G/M phase. Immunolabeling for phospho-Histone H3 in association with nocodazole to capture mitotic cells confirmed that HS impeded G to M transition. After excluding DNA damage-induced G arrest, it was revealed that HS reduced expression of Cyclin B1, CDK1, PLK1 and Aurora A at both protein and mRNA levels, with concomitant reduction of H3K4 tri-methylation at their promoter-regions. Animals that received oral administration of HS with a dosage relevant to clinical application showed reduced tumor volume and weight with a reduction of Cyclin B1, CDK1, PLK1 and Aurora A protein levels.
HS acts by impeding the G to M transition of prostate cancer cells. It is likely that the mode of action is transcriptionally suppressing proteins governing mitotic entry, without eliciting significant DNA damage.
HS 是一种古老的抗癌中药,由白花蛇舌草(H)和夏枯草(S)组成。当两者联合使用时,被称为 HS,是当今中国癌症患者最常用的中药之一。
疾病进展的预防是越来越多前列腺癌患者关注的焦点。本研究的目的是评估中药 HS 配方在抑制前列腺癌进展的临床前模型中的作用和作用机制。
通过评估增殖、细胞周期谱、DNA 损伤和负责 G 至 M 期过渡的关键调节剂,分析 HS 在前列腺癌细胞系中的作用。通过 RT-PCR 和 ChIP 测定这些调节剂的转录活性。在动物模型中验证 HS 的体外疗效。
HS 处理可观察到降低 DNA 含量并使前列腺癌细胞在 G/M 期积累。与长春新碱结合用于捕获有丝分裂细胞的磷酸化组蛋白 H3 的免疫标记证实,HS 阻碍了 G 至 M 期的转变。在排除 DNA 损伤诱导的 G 期阻滞后,发现 HS 降低了细胞周期蛋白 B1、CDK1、PLK1 和 Aurora A 的蛋白和 mRNA 水平,同时伴随其启动子区域 H3K4 三甲基化的降低。接受与临床应用相关剂量的 HS 口服给药的动物表现出肿瘤体积和重量的减少,同时细胞周期蛋白 B1、CDK1、PLK1 和 Aurora A 蛋白水平降低。
HS 通过阻碍前列腺癌细胞的 G 至 M 期转变发挥作用。其作用机制可能是转录抑制有丝分裂进入的蛋白质,而不会引起明显的 DNA 损伤。